MedPath

Dyne Therapeutics to Announce New Clinical Data from ACHIEVE Trial

Dyne Therapeutics, Inc. is set to reveal new clinical data from its Phase 1/2 ACHIEVE clinical trial on January 10, 2025, with a webcast scheduled for 8:00 a.m. ET. The company, focused on developing treatments for genetically driven neuromuscular diseases, will also provide a press release before the event.

Dyne Therapeutics, Inc., a clinical-stage company dedicated to creating life-transforming therapeutics for individuals with genetically driven diseases, has announced plans to disclose new clinical data from its Phase 1/2 ACHIEVE clinical trial. The announcement is scheduled for January 10, 2025, accompanied by a webcast at 8:00 a.m. ET. A press release will precede the event.
The live webcast will be accessible on the Events & Presentations page within the Investors & Media section of Dyne’s website, with a replay available for 90 days post-presentation. An accompanying slide presentation will also be provided. For access to the live webcast and replay, visit Dyne Therapeutics' Events & Presentations.
Dyne Therapeutics is at the forefront of discovering and advancing innovative therapeutics for genetically driven neuromuscular diseases. Utilizing its FORCE™ platform, the company is developing targeted treatments aimed at overcoming delivery challenges to muscle tissue and the central nervous system (CNS). Its pipeline includes clinical programs for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD).
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Dyne Therapeutics' DYNE-101 Shows Promise in DM1 Trial, FDA Grants Fast Track Designation

Dyne Therapeutics' DYNE-101 demonstrates compelling results in Phase 1/2 ACHIEVE trial for myotonic dystrophy type 1 (DM1).
The FDA grants Fast Track designation to DYNE-101, expediting its development and regulatory review process.

Acelyrin's Lonigutamab Shows Promise in Phase 2 Data for Thyroid Eye Disease

Acelyrin's lonigutamab demonstrates a potential best-in-class efficacy and safety profile for treating Thyroid Eye Disease (TED), according to updated Phase 2 data.
A virtual investor event on January 6, 2025, will feature clinician perspectives on unmet needs in TED and the design of the Phase 3 LONGITUDE program.

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

Immuneering Corporation announced it will hold a virtual Investor Event in early January 2025 to discuss data from its ongoing Phase 2a trial of IMM-1-104, including additional data from IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer, initial data from IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer, and initial data from IMM-1-104 monotherapy in second-line pancreatic cancer.

Biomea Fusion Announces Topline Results from Phase II COVALENT-111 Trial of Icovamenib in Type 2 Diabetes

Biomea Fusion will host a conference call on December 17, 2024, to present topline results from the Phase II COVALENT-111 trial of icovamenib in type 2 diabetes.
The COVALENT-111 trial evaluates the safety and efficacy of icovamenib, an oral covalent small molecule, in patients with type 2 diabetes.

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY001 in Healthy Volunteers

Spyre Therapeutics reports positive interim results from its Phase 1 trial of SPY001, a novel half-life extended anti-α4β7 antibody.
The trial, conducted on healthy volunteers, aimed to assess the safety, tolerability, and pharmacokinetics of SPY001.

IMUNON's IMNN-001 Receives FDA Agreement on Manufacturing for Phase 3 Ovarian Cancer Trial

IMUNON has secured FDA alignment on its Chemistry, Manufacturing, and Controls (CMC) strategy for IMNN-001, an immunotherapy targeting advanced ovarian cancer.
The FDA has accepted IMUNON's potency assay for measuring interferon-gamma (IFN-γ) levels, crucial for both Phase 3 trials and potential commercial use.

Neurona Therapeutics to Present at Upcoming Investor Conferences

Neurona Therapeutics will participate in William Blair's Innovator Series on October 3, presenting their advancements in regenerative cell therapies.
The company will also attend the Leerink Partners Biopharma Private Company Connect for investor meetings on October 22-23.

PepGen's PGN-EDO51 Shows Promise in Duchenne Muscular Dystrophy Trial

PepGen anticipates releasing preliminary data from its Phase II CONNECT1-EDO51 trial of PGN-EDO51 in mid-2024, offering a potential treatment for Duchenne muscular dystrophy (DMD).
The CONNECT1-EDO51 trial assesses the safety, exon 51 skipping, and dystrophin protein production in male patients with DMD amenable to exon 51 skipping.

Black Diamond Therapeutics Announces Phase 2 Data for BDTX-1535 in Recurrent EGFRm NSCLC

Black Diamond Therapeutics will present initial Phase 2 clinical trial results for BDTX-1535 in recurrent EGFRm NSCLC.
The webcast presentation is scheduled for Monday, September 23, 2024, at 8:00 a.m. ET.

Dyne Therapeutics' DYNE-251 Shows Promising Dystrophin Expression and Functional Improvements in Duchenne Muscular Dystrophy Trial

DYNE-251 demonstrated a mean absolute dystrophin expression of 3.71% of normal, over 10-fold higher than eteplirsen, in Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping.
Clinical data from the DELIVER trial indicated meaningful improvements in motor function, including the Stride Velocity 95th Centile, meeting clinically important benchmarks defined by the European Medicines Agency.

Reference News

[1]
Dyne Therapeutics to Host Investor Conference Call and ...
biospace.com · Jan 8, 2025

Dyne Therapeutics, Inc. will report new Phase 1/2 ACHIEVE clinical trial data on January 10, 2025, and host a webcast at...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy